Clinical Trial

All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated February 19, 2025 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-11-28; most recent amendment 2025-02-18.
Trial Details
NCT Number NCT06158412
Lead Sponsor The First Affiliated Hospital of Xiamen University
Conditions Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
Enrollment 25 participants
Start Date 2023-11-22
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-19